General Information of the Protein
Protein ID
PT03087
Protein Name
Protein arginine N-methyltransferase 5
Secondarily
Protein Name
72 kDa ICln-binding protein
Histone-arginine N-methyltransferase PRMT5
Jak-binding protein 1
Shk1 kinase-binding protein 1 homolog
Gene Name
PRMT5
Secondarily
Gene Name
HRMT1L5
IBP72
JBP1
SKB1
Sequence
MAAMAVGGAGGSRVSSGRDLNCVPEIADTLGAVAKQGFDFLCMPVFHPRFKREFIQEPAKNRPGPQTRSDLLLSGRDWNTLIVGKLSPWIRPDSKVEKIRRNSEAAMLQELNFGAYLGLPAFLLPLNQEDNTNLARVLTNHIHTGHHSSMFWMRVPLVAPEDLRDDIIENAPTTHTEEYSGEEKTWMWWHNFRTLCDYSKRIAVALEIGADLPSNHVIDRWLGEPIKAAILPTSIFLTNKKGFPVLSKMHQRLIFRLLKLEVQFIITGTNHHSEKEFCSYLQYLEYLSQNRPPPNAYELFAKGYEDYLQSPLQPLMDNLESQTYEVFEKDPIKYSQYQQAIYKCLLDRVPEEEKDTNVQVLMVLGAGRGPLVNASLRAAKQADRRIKLYAVEKNPNAVVTLENWQFEEWGSQVTVVSSDMREWVAPEKADIIVSELLGSFADNELSPECLDGAQHFLKDDGVSIPGEYTSFLAPISSSKLYNEVRACREKDRDPEAQFEMPYVVRLHNFHQLSAPQPCFTFSHPNRDPMIDNNRYCTLEFPVEVNTVLHGFAGYFETVLYQDITLSIRPETHSPGMFSWFPILFPIKQPITVREGQTICVRFWRCSNSKKVWYEWAVTAPVCSAIHNPTGRSYTIGL
    Show/Hide
Organism
Homo sapiens, Human
Protein Classification
Epigenetic regulator
>
Writer
>
Protein methyltransferase
>
Protein arginine methyltransferase
Function
Arginine methyltransferase that can both catalyze the formation of omega-N monomethylarginine (MMA) and symmetrical dimethylarginine (sDMA), with a preference for the formation of MMA (PubMed:10531356, PubMed:11152681, PubMed:11747828, PubMed:12411503, PubMed:15737618, PubMed:17709427, PubMed:20159986, PubMed:20810653, PubMed:21258366, PubMed:21917714, PubMed:22269951, PubMed:21081503). Specifically mediates the symmetrical dimethylation of arginine residues in the small nuclear ribonucleoproteins Sm D1 (SNRPD1) and Sm D3 (SNRPD3); such methylation being required for the assembly and biogenesis of snRNP core particles (PubMed:12411503, PubMed:11747828, PubMed:17709427). Methylates SUPT5H and may regulate its transcriptional elongation properties (PubMed:12718890). May methylate the N-terminal region of MBD2 (PubMed:16428440). Mono- and dimethylates arginine residues of myelin basic protein (MBP) in vitro. May play a role in cytokine-activated transduction pathways. Negatively regulates cyclin E1 promoter activity and cellular proliferation. Methylates histone H2A and H4 'Arg-3' during germ cell development (By similarity). Methylates histone H3 'Arg-8', which may repress transcription (By similarity). Methylates the Piwi proteins (PIWIL1, PIWIL2 and PIWIL4), methylation of Piwi proteins being required for the interaction with Tudor domain-containing proteins and subsequent localization to the meiotic nuage (By similarity). Methylates RPS10. Attenuates EGF signaling through the MAPK1/MAPK3 pathway acting at 2 levels. First, monomethylates EGFR; this enhances EGFR 'Tyr-1197' phosphorylation and PTPN6 recruitment, eventually leading to reduced SOS1 phosphorylation (PubMed:21917714, PubMed:21258366). Second, methylates RAF1 and probably BRAF, hence destabilizing these 2 signaling proteins and reducing their catalytic activity (PubMed:21917714). Required for induction of E-selectin and VCAM-1, on the endothelial cells surface at sites of inflammation. Methylates HOXA9 (PubMed:22269951). Methylates and regulates SRGAP2 which is involved in cell migration and differentiation (PubMed:20810653). Acts as a transcriptional corepressor in CRY1-mediated repression of the core circadian component PER1 by regulating the H4R3 dimethylation at the PER1 promoter (By similarity). Methylates GM130/GOLGA2, regulating Golgi ribbon formation (PubMed:20421892). Methylates H4R3 in genes involved in glioblastomagenesis in a CHTOP- and/or TET1-dependent manner (PubMed:25284789). Symmetrically methylates POLR2A, a modification that allows the recruitment to POLR2A of proteins including SMN1/SMN2 and SETX. This is required for resolving RNA-DNA hybrids created by RNA polymerase II, that form R-loop in transcription terminal regions, an important step in proper transcription termination (PubMed:26700805). Along with LYAR, binds the promoter of gamma-globin HBG1/HBG2 and represses its expression (PubMed:25092918). Symmetrically methylates NCL (PubMed:21081503). Methylates p53/TP53; methylation might possibly affect p53/TP53 target gene specificity (PubMed:19011621). Involved in spliceosome maturation and mRNA splicing in prophase I spermatocytes through the catalysis of the symmetrical arginine dimethylation of SNRPB (small nuclear ribonucleoprotein-associated protein) and the interaction with tudor domain-containing protein TDRD6 (By similarity).
    Show/Hide
Uniprot ID
Primary ID:
O14744

Secondarily ID:
A8MTP3
A8MZ91
B4DX49
B4DY30
B5BU10
D3DS33
E2QRE7
Q6IBR1
Q9UKH1
    Show/Hide
Ensembl ID
ENSG00000100462
HGNC ID
HGNC:10894
Subcellular Location
Cytoplasm
Nucleus
Chromosome
Golgi apparatus
Map of Molecular Bioactivity Related to the Protein
Map of Molecular Bioactivity Related to the Protein

Protein
Cell Line
Compound

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000068 , A-549
Compound ID Compound Name Compound Formula
CP0010708
(2R,3R,4S,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(1,8-diazaspiro[4.5]decan-1-ylmethyl)oxolane-3,4-diol
   Show/Hide
C19H28N6O3
 1
1
IC50 = 58 nM
   TI
   LI
   LO
   TS
CP0005352
(2R,3R,4S,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-[(8-methyl-1,8-diazaspiro[4.5]decan-1-yl)methyl]oxolane-3,4-diol
   Show/Hide
C20H30N6O3
 1
1
IC50 = 200 nM
   TI
   LI
   LO
   TS
CP0012418
(2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(1,8-diazaspiro[4.5]decan-1-ylmethyl)oxolane-3,4-diol
   Show/Hide
C18H27N7O3
 1
1
IC50 = 2300 nM
   TI
   LI
   LO
   TS
CP0014390
(2R,3S,4R,5R)-2-[[(2S)-2-(2-aminoethyl)pyrrolidin-1-yl]methyl]-5-(6-aminopurin-9-yl)oxolane-3,4-diol
   Show/Hide
C16H25N7O3
 1
1
IC50 = 2400 nM
   TI
   LI
   LO
   TS
CP0012651
(2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(pyrrolidin-1-ylmethyl)oxolane-3,4-diol
   Show/Hide
C14H20N6O3
 1
1
IC50 > 10000 nM
   TI
   LI
   LO
   TS
CP0013286
(2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(1-azaspiro[4.5]decan-1-ylmethyl)oxolane-3,4-diol
   Show/Hide
C19H28N6O3
 1
1
IC50 > 10000 nM
   TI
   LI
   LO
   TS
CP0014795
1-[1-[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl]-1,8-diazaspiro[4.5]decan-8-yl]ethanone
   Show/Hide
C20H29N7O4
 1
1
IC50 > 10000 nM
   TI
   LI
   LO
   TS
Biochemical Assays
Compound ID Compound Name Compound Formula
CP0015066
US10307413, Compound 188
   Show/Hide
C22H28N4O2
 1
1 IC50 = 4 nM
CP0019668
US10307413, Compound 208
   Show/Hide
C24H32N6O3
 1
1 IC50 = 6.2 nM
CP0563589
(2R,3R,4S,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-[(3,3-difluoro-1,8-diazaspiro[4.5]decan-1-yl)methyl]oxolane-3,4-diol;hydrochloride
   Show/Hide
C19H27ClF2N6O3
 1
1 IC50 = 8.7 nM
CP0011499
(1R,2S,3R,5S)-3-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-[2-[2-(cyclopropylmethylamino)quinolin-7-yl]ethyl]cyclopentane-1,2-diol
   Show/Hide
C26H30N6O2
 1
1 IC50 < 10 nM
CP0013807
(1R,2S,3R,5S)-3-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(2-quinolin-7-ylethyl)cyclopentane-1,2-diol
   Show/Hide
C22H23N5O2
 1
1 IC50 < 10 nM
CP0014041
(1R,2S,3R,5S)-3-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-[2-(2-aminoquinolin-7-yl)ethyl]cyclopentane-1,2-diol
   Show/Hide
C22H24N6O2
 1
1 IC50 < 10 nM
CP0003100
US10307413, Compound 337
   Show/Hide
C20H25N5O3
 4
1 IC50 = 22 nM
2 IC50 = 60 nM
3 IC50 = 110 nM
4 Kd = 11000 nM
CP0344323
(2R,3R,4S,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(1,8-diazaspiro[4.5]decan-1-ylmethyl)oxolane-3,4-diol;hydrochloride
   Show/Hide
C19H29ClN6O3
 1
1 IC50 = 22 nM
CP0008108
(2R,3R,4S,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-[(R)-hydroxy(phenyl)methyl]oxolane-3,4-diol
   Show/Hide
C17H18N4O4
 2
1 IC50 = 22 nM
2 Kd = 6 nM
CP0532845
2-(4-(4-(aminomethyl)-1-oxo-1,2- dihydrophthalazin-6-yl)-1-methyl-1H- pyrazol-5-yl)benzo[b]thiophene-3- carbonitrile
   Show/Hide
C22H16N6OS
 1
1 IC50 = 37 nM
CP0011023
AdoHcy
   Show/Hide
C14H20N6O5S
 1
1 IC50 = 200 nM
CP0488633
2-(4-(4-(aminomethyl)-1-oxo-1,2- dihydrophthalazin-6-yl)-1-methyl-1H- pyrazol-5-yl)-6-methoxybenzonitrile
   Show/Hide
C21H18N6O2
 1
1 IC50 = 1000 nM
CP0527986
2-(4-(4-(aminomethyl)-1-oxo-1,2- dihydrophthalazin-6-yl)-1-methyl-1H- pyrazol-5-yl)-6-cyclopropoxybenzonitrile
   Show/Hide
C23H20N6O2
 1
1 IC50 = 1000 nM
CP0567390
2-(4-(4-(aminomethyl)-1-oxo-1,2- dihydrophthalazin-6-yl)-1-methyl-1H- pyrazol-5-yl)-6-chlorobenzonitrile
   Show/Hide
C20H15ClN6O
 1
1 IC50 = 2000 nM
CP0575516
2-(4-(4-(aminomethyl)-1-oxo-1,2- dihydrophthalazin-6-yl)-1-methyl-1H- pyrazol-5-yl)-6-ethylbenzonitrile
   Show/Hide
C22H20N6O
 1
1 IC50 = 2000 nM
CP0527985
4-(aminomethyl)-6-(1-methyl-5-phenyl-1H- pyrazol-4-yl)phthalazin-1(2H)-one
   Show/Hide
C19H17N5O
 1
1 IC50 = 3000 nM
CP0542854
2-(4-(4-(aminomethyl)-1-oxo-1,2- dihydrophthalazin-6-yl)-1-methyl-1H- pyrazol-5-yl)-6-methylbenzonitrile
   Show/Hide
C21H18N6O
 1
1 IC50 = 3000 nM
CP0574592
2-(4-(4-(aminomethyl)-1-oxo-1,2- dihydrophthalazin-6-yl)-1-methyl-1H- pyrazol-5-yl)-3-fluorobenzonitrile
   Show/Hide
C20H15FN6O
 1
1 IC50 = 4000 nM
CP0579159
2-(4-(4-(aminomethyl)-1-oxo-1,2- dihydrophthalazin-6-yl)-1-methyl-1H- pyrazol-5-yl)benzonitrile
   Show/Hide
C20H16N6O
 1
1 IC50 = 4000 nM
Clinical Information about the Protein
Target 1 ( Protein arginine methyltransferase 5 (PRMT5) )
Target Type Clinical trial Target
Disease 2 Target-related Diseases  2
1 Breast cancer [ICD-11: 2C60-2C65]
2 Myelodysplastic syndrome [ICD-11: 2A37]
Clinical Trial Drug(s) 2 Clinical Trial Drugs  2
1 GSK3326595 Phase 2
Breast cancer
2 JNJ-64619178 Phase 1
Myelodysplastic syndrome